Sclerosis treatment market to reach $44.45b by 2034 as cases rise

Asia Pacific is expected to see strong growth.

The global multiple sclerosis treatment market is projected to grow to $44.45b by 2034, driven by rising prevalence and increased awareness of early diagnosis, according to a Maximise Market Research report. 

Growing demand for disease-modifying therapies and expanding access to advanced neurological care are also contributing to the market’s growth.

However, the high cost of long-term treatment and specialised neurological care is limiting patient access.

The report noted that expensive monoclonal antibody therapies and innovative treatments with limited reimbursement coverage in emerging economies further restrict market adoption.

Regionally, North America held the largest market share in 2025, supported by high MS prevalence, advanced healthcare infrastructure, strong neurological research, and high healthcare expenditure.

Meanwhile, Asia Pacific is expected to see strong growth as healthcare infrastructure, neurological disease awareness, diagnostic capabilities, and access to advanced MS therapies improve.

China, Japan, India, South Korea, and Australia are amongst the regional markets driving this development.

“Rising healthcare expenditure, pharmaceutical investments, clinical trials, and neurological research are creating new opportunities for advanced MS treatment adoption in the region,” the report added.